Cogent

Business

Cogent stock slumps after data for rare disorder therapy

Baris-Ozer Cogent Biosciences (NASDAQ:COGT) lost ~56% on Monday after announcing data from an ongoing Phase 2 trial for its lead…

Read More »
Back to top button